Loading…
Lobbying Spend
—
Filings
11
Firms Hired
1
Active Period
2017–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Making Pharmaceutical Markets More Competitive Act
2017 · first_quarter · Firm: BALLARD SPAHR LLP
CMS approval of proposed amendment to Arizona Health Care Cost Containment System's 1115 Research and Demonstration Waiver, which seeks an exemption from the Institutions for Mental Diseases exclusion for all beneficiaries ages 21-64, regardless of delivery system.
Client expense: — · Firm income: —
Matched citations: s 1115
Making Pharmaceutical Markets More Competitive Act
2017 · first_quarter · Firm: BALLARD SPAHR LLP
CMS approval of proposed amendment to Arizona Health Care Cost Containment System's 1115 Research and Demonstration Waiver, which seeks an exemption from the Institutions for Mental Diseases exclusion for all beneficiaries ages 21-64, regardless of delivery system.
Client expense: — · Firm income: —
Matched citations: s 1115
Source: Senate LDA